Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Endocrinology

  • 1
    News

    Assessing the efficacy and safety of dapagliflozin in patients with HFrEF

    April 22, 2021

    Can the use of dapagliflozin, in addition to guideline-directed medical therapy, improve patient-reported outcomes and health-related quality of life in patients with heart failure and reduced ejection fraction (HFrEF)?

  • 1
    News

    Dapagliflozin may cut risk of HF hospitalization in patients with type 2 diabetes

    March 25, 2021

    What is the Food and Drug Administration–approved indication for dapagliflozin (Farxiga)?

  • News

    COVID-19 can cause atypical thyroid inflammation

    March 24, 2021

    Patients with thyroid abnormalities during acute COVID-19, or who develop such symptoms, should have thyroid function checked every 6 months for a year.

  • News

    High obesity rates in Southern states magnify COVID threats

    March 19, 2021

    At least 29 states have green-lighted obesity for inclusion in the first phases of the COVID-19 vaccine rollout. That could overwhelm government efforts and heighten competition for scarce doses.

  • News

    ‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg

    March 16, 2021

    “[Chapter one] of the guidelines is devoted to blood pressure measurement ... if [targeting] 120 [mm Hg systolic], the emphasis is on 120 measured properly.”

  • 1
    News

    Don’t discontinue osteoporosis meds for COVID-19 vaccines, expert guidance says

    March 11, 2021

    Recommendations help physicians distinguish between a reaction to the vaccine and a reaction to medication.

  • 1
    News

    Inpatient sodium imbalances linked to adverse COVID-19 outcomes

    March 11, 2021

    Hypernatremia during hospitalization was associated with increased COVID-19 mortality and to a greater need for ventilatory support.

  • News

    Call to action on obesity amid COVID-19 pandemic

    March 9, 2021

    Hundreds of thousands of deaths worldwide from COVID-19 could have been avoided if obesity rates were lower; call for people with obesity to be included in priority lists for COVID-19 vaccination.

  • 1
    News

    Heart failure redefined with new classifications, staging

    March 8, 2021

    Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.

  • 1
    News

    Thirteen percent of patients with type 2 diabetes have major ECG abnormalities

    March 2, 2021

    ECGs from more than 8,000 Dutch patients with type 2 diabetes, most without known cardiovascular disease, show that major abnormalities are not unusual.

Previous1 2 3 4 5 6 … 17Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Style Guide for Authors
  • Subscribe
  • Advertise
  • Copyright © 2000-2022 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement